AbbVie waives license restrictions on HIV drug that may treat COVID-19

AbbVie is waiving all restrictions on licenses for its HIV drug, Kaltera, to allow it to be made anywhere in the world after it was shown to be somewhat effective in treating COVID-19 in preliminary trials, STAT reported. 

A nonprofit group called the Medicines Patent Pool has had licensing rights to the drug for the last five years. The deal was criticized for being too restrictive, as high-income countries were denied access to the drug, according to STAT

Since Kaltera has shown to be somewhat effective in treating COVID-19, AbbVie said it would dedicate the intellectual property rights for the drug to the public. 

“The big win here may be for people for HIV. Access to [Kaltera] has been a battle for years,” Ellen ‘t Hoen, a senior researcher in the global health unit at the University of Groningen in the Netherlands, told STAT

Read the full article here

More articles on pharmacy:
CVS Health recruiting 50,000 workers amid COVID-19 pandemic
69 experimental COVID-19 drugs, treatments identified
Physicians found hoarding experimental COVID-19 treatments for relatives, report says

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers